Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - raloxifene - film-coated tablet - 60 milligram(s) - selective estrogen receptor modulators; raloxifene

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: polysorbate 80; magnesium stearate; hypromellose; crospovidone; citric acid monohydrate; microcrystalline cellulose; titanium dioxide; macrogol 400; povidone - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: hypromellose; macrogol 400; povidone; microcrystalline cellulose; crospovidone; citric acid monohydrate; polysorbate 80; titanium dioxide; magnesium stearate - raloxifene is indicated for the prevention and treatment of osteoporosis in post-menopausal women.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride tablets, usp is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] . raloxifene hydrochloride tablets, usp is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . raloxifene hydrochloride tablets, usp is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participan

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride tablets are indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2) ]. raloxifene hydrochloride tablets are indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3) ]. raloxifene hydrochloride tablets are indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4) ]. the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4) ]. twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atyp

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - raloxifene hydrochloride -

Israel - English - Ministry of Health

eli lilly israel ltd, israel - raloxifene hydrochloride - film coated tablets - raloxifene hydrochloride 60 mg - raloxifene - raloxifene - evista is indicated for the treatment of osteoporosis in post menopausal women. evista is indicated for the prevention of osteoporosis in post menopausal women . evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - raloxifene hydrochloride 60mg equivalent to 55.7 mg raloxifene free base - film coated tablet - 60 mg - active: raloxifene hydrochloride 60mg equivalent to 55.7 mg raloxifene free base excipient: carnauba wax crospovidone lactose lactose monohydrate magnesium stearate opacode blue s-1-10537g opadry white ys-1-18027-a polysorbate 80 povidone

United States - English - NLM (National Library of Medicine)

a-s medication solutions - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride is indicated for the treatment and prevention of osteoporosis in postmenopausal women [see clinical studies (14.1, 14.2)] .  raloxifene hydrochloride is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [see clinical studies (14.3)] . raloxifene hydrochloride is indicated for the reduction in risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer [see clinical studies (14.4)] . the effect in the reduction in the incidence of breast cancer was shown in a study of postmenopausal women at high risk for breast cancer with a 5-year planned duration with a median follow-up of 4.3 years [see clinical studies (14.4)] . twenty-seven percent of the participants received drug for 5 years. the long-term effects and the recommended length of treatment are not known. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperpl

Canada - English - Health Canada

teva canada limited - raloxifene hydrochloride - tablet - 60mg - raloxifene hydrochloride 60mg - estrogen agonist-antagonists